
|Articles|December 1, 2003
Off-label Can Be on Target
Las Vegas - Much of what is new in dermatologic therapy represents off-label use of marketed drugs, but clinicians should not let that fact necessarily deter them from prescribing what may be very safe and effective therapy, said Stephen Stone, M.D., at the Fall Clinical Dermatology Conference.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
The “6-7” Advances for Dermatologists to Look Forward to in 2026
2
Quoin Targets World’s First Approval for Netherton Syndrome Therapy in Saudi Arabia
3
Obagi Launches ALOHA Program to Capture Real-World Insights in Aesthetic Injectables
4
Exploring Type 2 Inflammation and Psoriasis Management at Horizons in Advanced Practice
5



















